The unexpected PD-L1 suppression function of celery-derived extracellular vesicles improves lung cancer chemotherapy efficacy

Abstract

Aim: The article explores celery-derived extracellular vesicles (CDEVs), characterized by high cellular uptake, low immunogenicity, and high stability, as a therapeutic strategy for antitumor nanomedicines.

Methods: The methods employed in this study include in vitro cell experiments such as co-culture, Western Blot, and flow cytometry. In vivo experiments were conducted in C57BL/6 tumor-bearing mice subcutaneously injected with Lewis lung carcinoma (LLC) cells. The experiments encompassed parameters such as survival rate, body weight, tumor size, flow cytometry, immunohistochemistry, and spectral live imaging system.

Results: Our study revealed that CDEVs could be used as drugs to effectively downregulate the phosphorylated signal transducer and activator of transcription 3 (p-STAT3)/programmed cell death ligand 1 (PD-L1) axis in lung cancer cells. In co-culture experiments, CDEVs were observed to impede the expression of PD-L1, thereby interfering with the interaction between PD-L1 and programmed death 1 (PD-1) and subsequently preventing the suppression of T cells. In in vivo distribution experiments, CDEVs loaded with paclitaxel (PTX) demonstrated better tumor targeting capabilities. Remarkably, following CDEVs-PTX treatment, CD8+ T cell levels in mice were increased, presumably leading to improved antitumor effects.

Conclusion: CDEVs not only serve as drug carriers but also function as drugs themselves; as such, through a single administration of CDEVs, it is possible to combine immunotherapy and chemotherapy to achieve better effects between the two, providing a more comprehensive and effective cancer treatment strategy that promises to improve treatment outcomes and reduce the adverse effects of therapy.

Keywords

Celery-derived extracellular vesicles (CDEVs) / PD-L1 / CD8+ T cell / paclitaxel (PTX)

References

[1] Siegel RL,Jemal A.Cancer statistics, 2024.CA Cancer J Clin2024;74:12-49

[2] The Lancet.Lung cancer: some progress, but still a lot more to do.Lancet2019;394:1880

[3] Siegel RL,Jemal A.Cancer statistics, 2020.CA Cancer J Clin2020;70:7-30

[4] Paul M, Ohashi PS. The roles of CD8⁺ T cell subsets in antitumor immunity.Trends Cell Biol2020;30:695-704

[5] Gebhardt T,Parish IA.Stem-like exhausted and memory CD8⁺ T cells in cancer.Nat Rev Cancer2023;23:780-98

[6] Sharma P.Dissecting the mechanisms of immune checkpoint therapy.Nat Rev Immunol2020;20:75-6

[7] Marzec M,Goradia A.Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).Proc Natl Acad Sci U S A2008;105:20852-7 PMCID:PMC2634900

[8] Mortezaee K.Mechanisms of CD8⁺ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1.Biomed Pharmacother2023;163:114824

[9] Hughes PE,Wu LC.Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer.Trends Immunol2016;37:462-76

[10] Fehrenbacher L, Spira A, Ballinger M, et al; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46.

[11] Muro K,Shankaran V.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.Lancet Oncol2016;17:717-26

[12] Bardhan K,Boussiotis VA.The PD1:PD-L1/2 pathway from discovery to clinical implementation.Front Immunol2016;7:550 PMCID:PMC5149523

[13] De Ruysscher D,Nackaerts K.Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer.Ann Oncol2020;31:41-9

[14] Tian Y,Song J.A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.Biomaterials2014;35:2383-90

[15] Li MY,Dong M.Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis.Mol Cancer2021;20:22 PMCID:PMC7839206

[16] Woodman C,George A.Applications and strategies in nanodiagnosis and nanotherapy in lung cancer.Semin Cancer Biol2021;69:349-64

[17] Dad HA,Zhu AQ,Peng LH.Plant exosome-like nanovesicles: emerging therapeutics and drug delivery nanoplatforms.Mol Ther2021;29:13-31 PMCID:PMC7791080

[18] Alzahrani FA,Kameli N,Riza YM.Plant-derived extracellular vesicles and their exciting potential as the future of next-generation drug delivery.Biomolecules2023;13:839 PMCID:PMC10216196

[19] Orefice NS,Mizzoni D,Fais S.Purposing plant-derived exosomes-like nanovesicles for drug delivery: patents and literature review.Expert Opin Ther Pat2023;33:89-100

[20] Wang Q,Mu J.Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids.Nat Commun2013;4:1867 PMCID:PMC4396627

[21] Mu N,Zeng L.Plant-derived exosome-like nanovesicles: current progress and prospects.Int J Nanomedicine2023;18:4987-5009 PMCID:PMC10492547

[22] Kim J,Zhang S.Plant-derived exosome-like nanoparticles and their therapeutic activities.Asian J Pharm Sci2022;17:53-69 PMCID:PMC8888139

[23] Li MY,Wang F,Xu ZS.Advances in the research of celery, an important Apiaceae vegetable crop.Crit Rev Biotechnol2018;38:172-83

[24] Mencherini T,Bianco G,Aquino RP.An extract of Apium graveolens var. dulce leaves: structure of the major constituent, apiin, and its anti-inflammatory properties.J Pharm Pharmacol2007;59:891-7

[25] Lu X,Chen J.Celery (Apium graveolens L.) exosome-like nanovesicles as a new-generation chemotherapy drug delivery platform against tumor proliferation.J Agric Food Chem2023;71:8413-24

[26] Lian MQ,Liang J.Plant-derived extracellular vesicles: recent advancements and current challenges on their use for biomedical applications.J Extracell Vesicles2022;11:e12283 PMCID:PMC9753580

[27] Lee DY,Yoon D.Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals.Semin Cancer Biol2022;86:1033-57

[28] Gupta M,Sarwat M.Natural products and their derivatives as immune check point inhibitors: targeting cytokine/chemokine signalling in cancer.Semin Cancer Biol2022;86:214-32

[29] Nemati M,Mir RA.Plant-derived extracellular vesicles: a novel nanomedicine approach with advantages and challenges.Cell Commun Signal2022;20:69 PMCID:PMC9128143

[30] Cai Q,Shi T.Extracellular vesicles: cross-organismal RNA trafficking in plants, microbes, and mammalian cells.Extracell Vesicles Circ Nucl Acids2023;4:262-82 PMCID:PMC10419970

[31] Yi Q,Thakur A.Current understanding of plant-derived exosome-like nanoparticles in regulating the inflammatory response and immune system microenvironment.Pharmacol Res2023;190:106733

[32] Maeda H,Fang J.The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.Adv Drug Deliv Rev2013;65:71-9

[33] Wei G,Yang G,Ju R.Recent progress in nanomedicine for enhanced cancer chemotherapy.Theranostics2021;11:6370-92 PMCID:PMC8120226

[34] Sun R,Zhou Q.The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives.Adv Drug Deliv Rev2022;191:114614

[35] Cheng Z,Gurrieri E.Lipid-based nanosystems: the next generation of cancer immune therapy.J Hematol Oncol2024;17:53 PMCID:PMC11265205

[36] Wu M,Xie Y.Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.J Hematol Oncol2022;15:24 PMCID:PMC8917703

[37] Tong M,Jiang N,Li D.Correlation between p-STAT3 overexpression and prognosis in lung cancer: a systematic review and meta-analysis.PLoS One2017;12:e0182282 PMCID:PMC5552221

[38] Ai L,Xu J.Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. In: Xu J, editor. Regulation of cancer immune checkpoints. Singapore: Springer; 2020. pp. 33-59.

[39] Blank C,Peterson AC.PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8⁺ T cells.Cancer Res2004;64:1140-5